Linical (2183) Stock Overview
A global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
2183 Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Linical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥293.00 |
| 52 Week High | JP¥367.00 |
| 52 Week Low | JP¥258.00 |
| Beta | 0.19 |
| 1 Month Change | -2.98% |
| 3 Month Change | -14.33% |
| 1 Year Change | -15.80% |
| 3 Year Change | -55.74% |
| 5 Year Change | -64.66% |
| Change since IPO | -21.87% |
Recent News & Updates
Linical's (TSE:2183) Dividend Will Be ¥16.00
Dec 01Linical's (TSE:2183) Dividend Will Be ¥16.00
Nov 17Recent updates
Shareholder Returns
| 2183 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 0.7% | -1.9% | -0.2% |
| 1Y | -15.8% | -6.8% | 22.0% |
Return vs Industry: 2183 underperformed the JP Life Sciences industry which returned -6.8% over the past year.
Return vs Market: 2183 underperformed the JP Market which returned 22% over the past year.
Price Volatility
| 2183 volatility | |
|---|---|
| 2183 Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 8.0% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 2183 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 2183's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 598 | Kazuhiro Hatano | www.linical.com/ja |
Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariats; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management.
Linical Co., Ltd. Fundamentals Summary
| 2183 fundamental statistics | |
|---|---|
| Market cap | JP¥6.62b |
| Earnings (TTM) | -JP¥1.19b |
| Revenue (TTM) | JP¥9.87b |
Is 2183 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2183 income statement (TTM) | |
|---|---|
| Revenue | JP¥9.87b |
| Cost of Revenue | JP¥7.74b |
| Gross Profit | JP¥2.13b |
| Other Expenses | JP¥3.32b |
| Earnings | -JP¥1.19b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -52.51 |
| Gross Margin | 21.61% |
| Net Profit Margin | -12.02% |
| Debt/Equity Ratio | 31.4% |
How did 2183 perform over the long term?
See historical performance and comparisonDividends
Does 2183 pay a reliable dividends?
See 2183 dividend history and benchmarks| Linical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 11 2026 |
| Days until Ex dividend | 86 days |
| Days until Dividend pay date | 159 days |
Does 2183 pay a reliable dividends?
See 2183 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/01 08:07 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Linical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Masao Yoshida | Ichiyoshi Research Institute Inc. |
| Michael Newman | Macquarie Research |
| Yasunori Hiromoto | Marusan Securities Co. Ltd. |
